Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALB | P02768 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964637 | 0.89 | CCKBR (0.61) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2265093 | 0.89 | CCKBR (0.61) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2265026 | 0.86 | CCKBR (0.58) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2119839 | 0.86 | CCKBR (0.56) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2117547 | 0.85 | CCKBR (0.59) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2119671 | 0.85 | CCKBR (0.57) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2117818 | 0.83 | CCKBR (0.55) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2117932 | 0.83 | CCKBR (0.55) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL2262529 | 0.83 | CCKBR (0.58) | CCKBRLMNAMEN1ALBKMT2A | |
| SCHEMBL11964631 | 0.83 | CCKBR (0.58) | CCKBRLMNAMEN1ALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604023-B2 | 1,4-benzodiazepinone compounds and their use in treating cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | HTR4, HTR1A, HTR3B | CCKBR 714/4885LMNA 2242/4885MEN1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.